Abstract Parkinson's disease (PD), the second most common age-associated
neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and …

Parkinson's disease (PD) is the second most common age-associated neurodegenerative
disorder and is characterised by progressive loss of dopamine neurons in the substantia …

Background Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce dopaminergic neuron
degeneration in animal models of Parkinson disease (PD). However, no epidemiological …

Research into the pathogenesis of Parkinson's disease has been rapidly advanced by the
development of animal models. Initial models were developed by using toxins that …

Idiopathic Parkinson's disease (PD) represents a complex interaction between the inherent
vulnerability of the nigrostriatal dopaminergic system, a possible genetic predisposition, and …

Parkinson's disease (PD) affects one in every 100 persons above the age of 65 years,
making it the second most common neurodegenerative disease after Alzheimer's disease …

In mice, the systemical or intracranial application of the neurotoxin 1-methyl-4-phenyl-1, 2, 3,
6-tetrahydropyridine (MPTP) can lead to severe damage to the nigrostriatal dopaminergic …

We investigated whether nonsteroidal antiinflammatory drug use was associated with a
lower risk for Parkinson's disease (PD) in a large cohort of US men and women. PD risk was …

The glial reaction is generally considered to be a consequence of neuronal death in
neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, and …

Parkinson's disease (PD) is characterised by degeneration of dopaminergic neurons in the
substantia nigra pars compacta (SNpc). Inflammation may be associated with the …